文献速递肺外科

健康八旬早期肺癌:肺叶切除与SBRT生存比较

Lobectomy Versus Stereotactic Body Radiotherapy in Healthy Octogenarians With Stage I Lung Cancer.
PubMed 文献 · Ann Thorac Surg · 2020-09-03

本研究基于美国国家癌症数据库,比较80岁及以上无合并症、临床I期非小细胞肺癌患者接受肺叶切除或立体定向放疗(SBRT)的长期生存。倾向评分匹配后,肺叶切除(清扫≥7枚淋巴结)中位生存74个月,优于SBRT的53.2个月;但未清扫淋巴结时两组无差异。多因素分析显示肺叶切除与生存改善独立相关(HR 0.726)。

要点

  • 健康八旬I期肺癌,肺叶切除联合充分淋巴结清扫生存优于SBRT。
  • 淋巴结清扫数量影响分期与生存获益,未清扫时优势消失。
  • 年龄、性别、高级别、肿瘤大小是独立生存预测因素。

核心结论

  • 在健康、适合手术的八旬临床I期非小细胞肺癌患者中,肺叶切除生存优于SBRT。
  • 充分淋巴结清扫可实现真实淋巴结分期,并在发现隐匿转移时提供辅助治疗机会。

研究设计与样本

  • 回顾性队列研究,查询美国国家癌症数据库。
  • 纳入临床IA/IB期(肿瘤≤40 mm)非小细胞肺癌、无合并症、接受SBRT或肺叶切除的患者。
  • 肺叶切除8964例,SBRT 286例;采用倾向评分匹配调整治疗组。
  • 按检出淋巴结数将肺叶切除分为0枚、1–6枚、≥7枚三组。
  • 采用Kaplan-Meier和多因素Cox回归进行生存分析。

主要发现

  • 倾向匹配后,肺叶切除(≥7枚淋巴结)较SBRT显著改善生存(中位74 vs 53.2个月,P < .05)。
  • 0枚淋巴结清扫时两组生存无差异(中位53.8 vs 52.3个月,P = .88)。
  • 多因素分析中肺叶切除与生存改善显著相关(HR 0.726;95%CI 0.580–0.910;P = .005)。
  • 年龄、性别、高级别和肿瘤大小是生存的独立预测因素。

临床怎么用

  • 对健康、可手术的八旬I期非小细胞肺癌患者,肺叶切除联合充分淋巴结清扫可带来生存获益。
  • 淋巴结清扫数量应足够(至少7枚)以实现准确分期并指导辅助治疗。

局限性

  • 回顾性数据库研究,存在选择偏倚,SBRT组样本量远小于手术组。
  • 仅纳入无合并症患者,结论不能外推至有合并症的八旬人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stereotactic body radiation therapy (SBRT) is increasingly being offered for early stage non-small cell lung cancer (NSCLC). We sought to evaluate long-term survival outcomes after lobectomy and SBRT in patients aged 80 years or more with stage I NSCLC. METHODS: The National Cancer Database was queried for patients with clinical stage IA and IB (size 40 mm or smaller) NSCLC who underwent SBRT or lobectomy. Only patients with no comorbidities were selected. Number of lymph nodes (LN) examined was used to stratify lobectomy patients into 0 LN, 1 to 6 LN, and 7 or more LN. Propensity score analysis was used to adjust treatment groups. Kaplan-Meier and multivariate Cox regression analysis were used for survival analysis. RESULTS: A total of 8964 patients with stage I NSCLC treated with lobectomy were compared with 286 patients who received SBRT. Using propensity matched pairs, lobectomy (7 LN or more) had significantly improved survival as compared with SBRT (median 74 vs 53.2 months, P < .05); however, no survival differences were observed when 0 LN were sampled (median 53.8 vs 52.3 months, P = .88). In multivariate analysis, lobectomy was associated with significantly improved survival (hazard ratio 0.726; 95% confidence interval; 0.580 to 0.910; P = .005). In addition, age, sex, high grade, and tumor size were independent predictors of survival. CONCLUSIONS: Among healthy octogenarians with clinical stage I NSCLC who are good surgical candidates, lobectomy offers better survival than SBRT. Adequate LN dissection allows true nodal staging and opportunity for adjuvant treatment when unsuspected nodal metastases are found.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Razi SS, Kodia K, Alnajar A, et al. Lobectomy Versus Stereotactic Body Radiotherapy in Healthy Octogenarians With Stage I Lung Cancer. Ann Thorac Surg. 2020. PMID: 32891656. doi:10.1016/j.athoracsur.2020.06.097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。